TECHNETIUM AND RHENIUM IN NUCLEAR MEDICINE

人造元素锝，以其短暂的伽马射线形式存在 放射性核素99mTc在常规核试验中起着非常重要的作用， 医学成像 在美国，超过85%的手术涉及 施用99mTc标记的放射性药物。 此续订 应用程序描述了一个持续的研究计划，结合基本的 元素的化学研究及其应用 设计新的成像剂。 此外，A parallel 该项目将探索与之密切相关的金属元素的化学性质 及其在放射治疗中的应用。 锝的基础研究将包括使用新的合成 在当前周期中发现的中间体， 开发低氧化态化学，使用氮供体配体 形成低和高氧化态的新络合物， 金属有机化学研究。 新战略将是 研究锝与生物活性分子的结合 使用几种不同类型的复合物， 用于生物配体附着的位点。 的首次应用 化学将涉及各种阳离子的研究 作为心肌显像剂的锝络合物， 组织的代谢状态。 这些代理人将是重要的 缺血事件后可挽救组织的评估。 第二 该地区将探索几种肿瘤检测的途径，包括 相对简单的阳离子复合物和99mTc标记的自然杀伤细胞（NK） 细胞 在电化学的应用中， 将设计在示踪剂浓度下合成所需的化合物。 这将基本上平行于早期的发展锝 化学. 这种化学反应将用于寻找可溶性的 适用于放射性滑膜切除术的药物，特别是用于治疗 类风湿性关节炎和色素沉着绒毛结节性滑膜炎。 使用 可溶性药物可以使这种疗法在小于 膝盖和脚踝。

The artificial element technetium, in the form of its short-lived gamma ray emitting radionuclide 99mTc, plays a very important role in routine nuclear medicine imaging. More than 85% of all procedures in the USA involve the administration of a 99mTc-labeled radiopharmaceutical. This renewal application describes a continuing program of research that combined basic chemical studies of the element together with applications of that chemistry towards the design of new imaging agents. In addition a parallel program will explore the chemistry of the closely related metallic element rhenium and its applications in radiotherapy. The basic studies of technetium will include the use of new synthetic intermediates discovered in the current cycle to explore the rapidly developing low-oxidation-state chemistry, the use of nitrogen donor ligands to form new complexes in low and high oxidation states, and an investigation of its organometallic chemistry. New strategies will be investigated for conjugation of technetium to biologically active molecules using several different classes of complexes that leave free coordinating sites for the attachment of biological ligands. The first application of the chemistry will involve an investigation of a variety of cationic technetium complexes as myocardial imaging agents that are sensitive to the metabolic state of the tissue. Such agents would be important in the evaluation of salvageable tissue following an ischemic event. The second area will explore several avenues towards tumor detection, including relatively simple cationic complexes and 99mTc-labeled natural killer (NK) cells. In the applications of rhenium chemistry, reliable methods for synthesizing required compounds at tracer concentrations will be devised. This will essentially parallel earlier developments in technetium chemistry. This chemistry will then be applied to a search for soluble agents suitable for radiation synovectomy, particularly for treatment of rheumatoid arthritis and pigmented villonodular synovitis. The use of soluble agents may allow a wider use of this therapy in joints smaller than the knee and ankle.